González Barón M, Feliu J, Garcia Girón C, Espinosa J, Martinez B, Blanco E, Crespo M C, Ordóñez A, Espinosa E, de Castro J, Juárez F, Colmenarejo A
Hospital General La Paz, Madrid, Spain.
Oncology. 1997;54 Suppl 1:24-9. doi: 10.1159/000227742.
A phase II trial of UFT (Tegafur and Uracil) modulated by leucovorin was undertaken by the Oncopaz Cooperative Group to assess the efficacy and toxicity of this combination in patients with advanced colorectal cancer. A total of 75 patients were given 500 mg/m2 intravenous leucovorin and 195 mg/m2 of oral UFT on day 1, followed by oral leucovorin 15 mg/12 h and 195 mg/m2/12 h of oral UFT on days 2-14. An overall response rate of 39% was obtained, with seven complete responses (9%), and 22 partial responses (29%). The primary toxicity was gastrointestinal, with grade 1-2 diarrhea occurring in 8.5% of courses, and grade 3-4 in 3.5%. Hematologic toxicity was minimal, and there were no deaths due to toxicity. This regimen was active and well tolerated in patients with advanced colorectal cancer, including those 70 years of age or older.
肿瘤学合作组开展了一项由亚叶酸钙调节的优福定（替加氟和尿嘧啶）II期试验，以评估该联合用药方案对晚期结直肠癌患者的疗效和毒性。共有75例患者在第1天接受500 mg/m²静脉注射亚叶酸钙和195 mg/m²口服优福定，随后在第2 - 14天接受15 mg/12 h口服亚叶酸钙和195 mg/m²/12 h口服优福定。总缓解率为39%，其中7例完全缓解（9%），22例部分缓解（29%）。主要毒性为胃肠道毒性，1 - 2级腹泻发生率为8.5%的疗程，3 - 4级为3.5%。血液学毒性极小，且无因毒性导致的死亡。该方案对晚期结直肠癌患者，包括70岁及以上患者有效且耐受性良好。
